Home > Insider Trading > Filing (0001209191-14-023496)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1513818	Versartis Inc.	VSAR	Pharmaceutical Preparations (2834)	244106690

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1380178	Shahzad Malik	C/O Advent Life Sciences 158 North Gower Street London X0 NW1 2ND		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-03-26	1,258,086	$0.00	1,258,086	No	4	C	Indirect	See FN
Common Stock	Acquisiton	2014-03-26	489,253	$0.00	1,747,339	No	4	C	Indirect	See FN
Common Stock	Acquisiton	2014-03-26	176,813	$0.00	1,924,152	No	4	C	Indirect	See FN
Common Stock	Acquisiton	2014-03-26	78,228	$0.00	2,002,380	No	4	C	Indirect	See FN
Common Stock	Acquisiton	2014-03-26	154,178	$0.00	2,156,558	No	4	C	Indirect	See FN
Common Stock	Acquisiton	2014-03-26	60,000	$21.00	2,216,558	No	4	P	Indirect	See FN

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See FN
No	4	C	Indirect	See FN
No	4	C	Indirect	See FN
No	4	C	Indirect	See FN
No	4	C	Indirect	See FN
No	4	P	Indirect	See FN

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Series B Convertible Preferred Stock	Warrants to Purchase Series B Preferred Stock	Disposition	2014-03-26	506,376	$0.00	506,376	$0.45
Common Stock	Series B Convertible Preferred Stock	Acquisiton	2014-03-26	506,376	$0.00	44,031	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2014-03-26	14,468,020	$0.00	1,258,086	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2014-03-26	5,626,413	$0.00	489,253	$0.00
Common Stock	Series D-1 Convertible Preferred Stock	Disposition	2014-03-26	2,033,350	$0.00	176,813	$0.00
Common Stock	Series D-2 Convertible Preferred Stock	Disposition	2014-03-26	899,619	$0.00	78,228	$0.00
Common Stock	Series E Convertible Preferred Stock	Disposition	2014-03-26	1,773,049	$0.00	154,178	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2014-03-26	No	4	X	Indirect
14,468,020		No	4	X	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect

Footnotes

In connection with the completion of the Issuer's initial public offering of Common Stock, each share of Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, Series D-1 Convertible Preferred Stock, Series D-2 Convertible Preferred Stock and Series E Convertible Preferred Stock automatically converted into Common Stock on a 1-for-11.5 basis.
Securities are held by Advent Life Sciences LLP ("Advent") and Advent Life Sciences Fund I LP ("Advent Fund"). Advent is the general partner of Advent Fund. The reporting person is a partner of Advent.
Immediately exercisable. In connection with the closing of the Issuer's initial public offering of Common Stock the warrant to purchase Series B Convertible Preferred Stock shall automatically convert into a warrant to purchase Common Stock on a 1-for-11.5 basis if the warrant is not otherwise exercised prior to such closing.
The securities do not have an expiration date. Each share of Series B, Series C, Series D-1, Series D-2 and Series E Convertible Preferred Stock converted automatically into shares of Common Stock in connection with the closing of the Issuer's initial public offering on March 26, 2014. Prior to its conversion into the Issuer's Common Stock, The Series B, Series C, Series D-1, Series D-2 and Series E Convertible Preferred Stock was convertible at any time at the option of the holder.